Centro Ricerche Cliniche Di Verona S.r.l.
- Address
- lock Available on a paid plan
Neoplasms
The Centro Ricerche Cliniche Di Verona Oncology department is engaged in a broad portfolio of cancer studies, emphasizing the testing of new targeted and immunotherapeutic approaches for advanced solid tumors.
- Metastatic non‑small cell lung cancer
- HER2‑positive gastric cancer
- Metastatic clear cell renal cell carcinoma
- High‑grade serous ovarian cancer
- MET‑driven papillary renal cell carcinoma
Across 154 trials and 56 investigators, the focus is on improving survival and response rates by evaluating novel agents and combination regimens.
Respiratory Tract Diseases
Research at the Verona site includes trials aimed at better control of severe asthma with an eosinophilic phenotype and other chronic lung conditions.
- Severe eosinophilic asthma
- Chronic obstructive pulmonary disease
- Idiopathic pulmonary fibrosis
- Bronchiectasis in cystic fibrosis
- Eosinophilic granulomatosis with polyangiitis
The trials aim to reduce medication burden, prevent exacerbations, and assess long‑term safety of emerging biologics.
Immune System Diseases
A series of studies target autoimmune disorders, exploring innovative biologic therapies to modulate immune activity.
- Systemic lupus erythematosus
- IgG4‑related disease
- Chronic spontaneous urticaria
- Rheumatoid arthritis flare management
- Polymyalgia rheumatica
Objectives include improving disease control while monitoring safety and tolerability of new agents.
Hemic and Lymphatic Diseases
Investigators are conducting trials on myelofibrosis and related hematologic malignancies, focusing on next‑generation JAK inhibitors and immunotherapies.
- Primary myelofibrosis
- Post‑polycythemia‑vera myelofibrosis
- Myelodysplastic syndromes
- Diffuse large B‑cell lymphoma
- Mantle cell lymphoma
The goal is to achieve durable hematologic responses and reduce transfusion dependence.
Digestive System Diseases
The site supports studies on gastrointestinal cancers and inflammatory conditions, testing precision medicines for gastro‑esophageal junction adenocarcinoma and other tumors.
- Metastatic colorectal cancer
- Advanced cholangiocarcinoma
- Gastric adenocarcinoma
- Pancreatic ductal adenocarcinoma
- Crohn’s disease
Research aims to improve survival, manage disease‑related symptoms, and identify predictive biomarkers.
Female Urogenital Diseases
Trials in this therapeutic area address cancers and reproductive health issues, including work on high‑risk non‑muscle invasive bladder cancer.
- High‑risk NMIBC
- Advanced ovarian cancer
- Uterine serous carcinoma
- Endometriosis‑related pain
- Hormone‑receptor positive breast cancer
Studies evaluate immunotherapy, targeted agents, and hormone‑modulating strategies to enhance outcomes.
Musculoskeletal Diseases
Research includes rare bone disorders and cancer‑related bone complications, such as osteogenesis imperfecta in pediatric patients.
- Osteogenesis imperfecta in children
- Bone metastases from solid tumors
- Paget disease of bone
- Rheumatoid arthritis joint inflammation
- Upper‑limb spasticity after stroke
The aim is to assess bone‑strengthening agents and functional rehabilitation outcomes.
Nervous System Diseases
Studies target neurological conditions, including symptom relief for essential tremor and disease modification in select disorders.
- Essential tremor
- Multiple sclerosis relapse management
- Neuropathic pain in cancer
- CNS involvement in lymphoma
- Neuroendocrine tumors of the lung
Objectives focus on improving quality of life and evaluating novel neuro‑protective therapies.
Skin and Connective Tissue Diseases
The Verona research program includes investigations of chronic skin and connective tissue disorders, such as chronic spontaneous urticaria.
- Chronic spontaneous urticaria
- Psoriatic arthritis skin manifestations
- Sjögren’s syndrome
- Systemic sclerosis
- Eosinophilic esophagitis
Trials assess efficacy of biologics and aim to reduce disease activity while enhancing patient‑reported outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 19 therapeutic areas and 15 of 248 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 244 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 65 by active trials.
- 1Incyte Corp.9active
lock +64 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.13trials
lock +38 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Ricerche Cliniche Di Verona S.r.l.
lock Showing 1 of 215 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Safety and Tolerability of ARV-806 in Adults with KRAS G12D-Mutated Advanced Solid Tumors | Arvinas Operations Inc. | Phase I | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 248 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 19 | Unknown | 2019-05-07 | 2026-01-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.